Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC762 in Advanced or Metastatic Solid Tumors
NCT04875806Phase 2Terminated
- Sponsor
- NextCure, Inc.
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of NC762 in solid tumor, metastatic solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC), breast cancer, sponsored by NextCure, Inc.. Started Jun 2021; status: terminated.
02
Drugs
NC762
03
Conditions
solid tumormetastatic solid tumorovarian cancernon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT04875806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875806.